Global Health Policy Blog

CGD experts blog on global health issues such as health financing, drug resistance, clinical trials, vaccine development, HIV/AIDS, and health-related foreign assistance.

 

Comments Needed: A Better Deal to Protect Americans’ Health under the Trump Administration

We would argue that investing in global health, at least along certain dimensions, is entirely consistent with President Trump’s philosophy of America First—a real opportunity for his administration to improve the security of the American people by pushing through some much-needed reform. In that spirit, we’ve put together a proposal for a new executive initiative under the Trump Administration. We call it PAHAA: Protecting America’s Health at Home and Abroad.

Health Technology Assessment: Global Advocacy and Local Realities

Cost-effectiveness analysis (CEA) can help countries attain and sustain universal health coverage (UHC), as long as it is context-specific and considered within deliberative processes at the country level. Institutionalising robust deliberative processes requires significant time and resources, however, and countries often begin by demanding evidence (including local CEA evidence as well as evidence about local values), whilst striving to strengthen the governance structures and technical capacities with which to generate, consider and act on such evidence. In low- and middle-income countries (LMICs), such capacities could be developed initially around a small technical unit in the health ministry or health insurer. The role of networks, development partners, and global norm setting organisations is crucial in supporting the necessary capacities.

Technology Won’t “Save” Healthcare

Health technologies can reduce healthcare spending. On average, they don’t. Prominent examples—like the way polio vaccines eliminated the need for iron lungs—seem to drive a common faith in healthcare technology as a tool to “cure” costly health systems. But it actually works the other way around—health systems (policies, institutions, and markets) and human responses to them determine whether these tools will (or won’t) increase spending.

She Decides, But Who Pays?

This week, representatives from 50-plus countries gathered in Brussels for the “She Decides” conference, raising about $190 million in pledges to support women’s reproductive and sexual health and rights around the world. This is great news, but the relatively small absolute scale of the pledges highlights the challenge of substituting for US financial and political leadership.

Global Fund Executive Director Reboot

This week, the Board of the Global Fund to Fight AIDS, Tuberculosis, and Malaria was set to name the organization’s new executive director. Instead, after the shortlist of candidates appeared in the New York Times, some in the global health community anonymously expressed concerns about the selection process and its results—and the Board abruptly announced it would restart the process from scratch. As the executive director search reboots, I am looking for candidates that have clarity, concrete plans, and capacity to make progress in three areas—the big 3—that are essential to the Fund’s survival: results, efficiency, and money.

Pages

Global Health Policy Blog

Tags

Experts